n Southern African Journal of HIV Medicine - From the editor




Extracted from text ... The article by Professor Robin Wood in this issue highlights the dilemma surrounding antiretroviral first-line regimens. We do have an effective, cheap, first-line therapy: however it contains d4T, which has toxicities. These have been noted and vary in prevalence in South Africa. The efficacy and cost of the current first-line therapy has to be balanced against the decreased toxicity and increased expense of a first-line therapy containing tenofovir (expected to be registered in South Africa in about 12 months). The increased costs of a tenofovircontaining regimen will include the higher cost of monitoring, this time for renal toxicities. On ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error